Replies to post #3763 on Arch Therapeutics Inc (ARTH)

[JUST 10-11-12]

thanks

[Regis999]

Study these and note size of numbers and dream about ARTH. Imagine if they did a deal for just 50 of the 200 potential applications.

I have been blown away at the size of some of these recent deals.

Remember we only need $ 8 to $ 12 million of additional capital to get all the human trials in Europe AND USA per SEC filings.

Study these recent deals to see how big the numbers have gotten:

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study (market cap $ 67 million---royalty in high teens)

"This morning, MEI $MEIP is taking the wraps off a development deal with Switzerland’s Helsinn designed to shepherd the HDAC inhibitor pracinostat through a pivotal study. MEI gets $20 million in near-term cash —$15 million up front with a $5 million milestone at the start of the Phase III — along with a $5 million equity investment. And there’s $444 million in milestones on the table for success, along with royalties that can be earned from Helsinn’s marketing efforts"


"Advaxis Inc. ADXS, +5.48% shares spiked 28% in pre-market trade Tuesday after the company announced a $40 million agreement with Amgen Inc. AMGN, -0.15% to develop and commercialize cancer immunotherapy treatment ADXS-NEO. The agreement includes a $40 million upfront payment to Advaxis and a $25 million purchase of the company's common stock by Amgen, along with sales milestone payments of up to $475 million and additional royalty payments based on global sales."

[21money21]

Yes Regis, what ce mark will allow is huge.. If bed sores included that's tremendous. If need to test for each indication, we are going to be waiting a while. They need to spell out a game plan for all of us investors that believe in this company and put our money and faith in them. We are entitled to it.

[Amatuer17]

Hi Regis - any comments on this post from SA

"Preclinical Mice vs Human trial results

ARTH had published at least 4 pre-clinical studies from Feb'15 to Apr'15

In all cases - AC5 showed TTH of less than 30 secs - which is significantly low.

Do we know what was actual TTH in these patients?

Here are comparisons from preclinical trial PRs

Gelatin - 4 times more time

Cellulose based Fibrin sealant - 4 times more time

Fibrin sealant - 50% more time

Gelatin thrombin hemostat - 200% (2 times) more time

Compared to these numbers - 41% less time looks not as attractive as animal studies - although it is very good.

Do we know which agent was used as comparator and what was absolute TTH?"

[BooDog]

Getting into more clinics afterwards is the bigger hurdle. I'm not sure what you mean by the different CE marking levels either. From what I see, it's marked or it isn't. I don't foresee any issues getting it marked. I would like to see Arch present at some of the major medical conferences in Europe. Time to get more exposure over yonder. As for conference calls, everyone communicating with the board, please impress the importance of doing web based calls vice phone in. Much more participation. People can still phone in to a web based call if need be. I'm thinking Arch will be expanding very quickly over the next several months and wouldn't at all be surprised to see a couple institutionals take a position. Even before uplisting.

As far as the CE Mark they are applying for a "top line" CE Mark which requires a little more time.